The Toronto site of the SGC seeks ambitious and adventurous cell and molecular biologists to work in a multidisciplinary environment to characterize mechanisms of epigenetic signaling using small molecule inhibitors of chromatin regulatory proteins. Projects include:
• Epigenetic plasticity of cancer stem cells and its pharmacological modulation
• MLL complex members: elucidating function and modulating activity in leukemia
• Roles of H3K36 methyltransferases in health and disease
• Arginine methyltransferases as novel targets in cancer
Recent selected publications from the project :
• Vedadi et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nature Chemical Biology 7:566-74 (2011)
• Filippakopoulos et al. Selective inhibition of BET bromodomains, Nature 468, 1067-73 (2010)
• James et al, Discovery of a chemical probe for a methyl-lysine reader domain: L3MBTL3, Nature Chemical Biology, ( 2013), Jan 6th Epub.
• Yu et al, Catalytic site remodeling of the DOT1L methyltransferase by selective inhibitors, Nature Comm. 3:1288 (2012).
Candidates should have 0-2 years experience post PhD, with strong experimental skills in one or more of the following: molecular cell biology, protein/RNA/DNA analysis (ChIP), cellular biochemistry, cell imaging, or chemical biology.
Interested Candidates please send CV to Cheryl Arrowsmith/Dalia Barsyte d.barsyte@utoronto.ca
The SGC is a not for profit, public-private partnership working with academia and pharmaceutical companies to carry out open access basic science relevant to human health and drug discovery.
http://www.thesgc.org and http://www.thesgc.org/scientists/epigenetics
The University of Toronto and its affiliated hospital research institutes comprise one of the largest and most productive centers of biomedical research in North America. Located in vibrant downtown Toronto, the University provides an outstanding opportunity for scientific research, and career development….
中国-博士人才网发布
